2/2/07 Update
A decent week for the Nasdaq Biotech Index, which closed Friday with a 3.15% YTD gain (vs. up 1.82% YTD at the prior Friday's close). The 31 Contest portfolios did a smidgen better than the NBI, closing the week with a median 3.48% YTD gain (vs. a 2.09% YTD gain at the prior Friday's close). At week's end, 23 of the 31 Contest portfolios were in the black and 17 of the 31 were beating the NBI.
Boosted again by Inex, my own portfolio held on to first place, closing Friday with a 43.4% YTD gain. (For the curious, without Inex, my portfolio would be tied with FRED for fifth place, with a 9.2% YTD gain.) Thanks in part to a late-week surge by SGEN, STEVEL (plus 20.4% YTD) raced ahead of TILEY (plus 14.4% YTD) to take the No. 2 position.
Below is the Top Ten list on 1/26/07:
2/2/07
Rank Name Total
1 BULBA 43,391
2 STEVEL 20,359
3 TILEY 14,382
4 WILDER 11,669
5 MANNY 9,714
6 FRED 9,227
7 QUID 7,365
8 TECHNET 6,778
9 PRAVEEN 5,829
10 NIGEL 5,099
(All corrections greatly appreciated.) |
